PMC8721166_01
The Clinical course of the disease, treatment history, and response evaluation. (A) Timeline of treatment and molecular profiling based on tissue and liquid biopsies. (B) Duration of disease response evaluated by CT and PET/CT. CT, computed tomography; PET/CT, positron-emission tomography/computed tomography.
fphar-12-809467-g001.jpg
PMC8721166_01_fphar-12-809467-g001.jpg
F1
A 39-year-old nonsmoking male presented to our hospital with chest pain in November 2017 (Figure 1A). Chest computed tomography (CT) demonstrated a 26-mm solid nodule in the hilum of the right lung (Figure 1B).
An overview of somatic mutation profiles within tissue and liquid biopsies using the next-generation sequencing technique. (A) Each row represents one individual biopsy sample, and each column represents one somatic genetic alteration. (B) Dynamic changes in the gene abundance of plasma ctDNA. Solid lines represent ALK mutations, and dashed lines represent concomitant mutations. ctDNA, circulating tumour DNA.
fphar-12-809467-g002.jpg
PMC8721166_01_fphar-12-809467-g002.jpg
F2
TP53 mutation (Figure 2A). The patient was administered crizotinib (250 mg twice daily) as the first-line treatment and achieved a partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The other resistance-associated ALK point mutations disappeared (Figure 2B).